MIT's Robert Langer took home the Queen Elizabeth Prize for his many contributions to drug delivery, including the development of controlled-release polymers, drug-delivering wafers and work on drug-eluting stents.
Researchers at the University of Maryland have taken to using soap bubbles as vehicles for drugs and vaccines. The biomolecule-tagged spheres have been shown to be cost-effective and able to work with a broad spectrum of therapeutics, the scientists say.
Now that AbbVie has followed up on Gilead's game-changing combo with its own directly competitive hep C cocktail, Merck's late-stage player in the field doesn't look quite as revolutionary as it once did. With a new drug application being prepped for a near-term filing, the FDA has decided to drop its breakthrough therapy designation for Merck, possibly slowing the Big Pharma's marketing timeline a bit.
Researchers from Bangalore's Indian Institute of Science have developed a novel microcapsule drug delivery mechanism for insulin using micro-shock waves that reduces the need for those oft-dreaded needles.
Revolution Medicines is developing technology it believes can do evolution one better, improving on naturally occurring compounds to transform promising but raw molecules into discrete drug candidates. And, with the help of $45 million from Third Rock Ventures, the biotech is first setting its sites on a pedigreed antifungal therapy.
Google is developing a wearable medical device consisting of a magnet that would collect ingested nanoparticles whose job it is to attach to cancerous cells and take them to the magnet. The nanoparticles convey data to the magnet by "lighting up" cancer cells, Andrew Conrad, the head of Google's life sciences unit, said.
Baxter is scaling back its support of Onconova's lead candidate, nixing plans to pay for European trials and paring down the potential of what could have been a $565 million deal for the biotech.
Isis Pharmaceuticals is touting positive mid-stage results for its in-development Type 2 diabetes treatment, which significantly improved blood sugar levels and body weight. But the company didn't disclose how the drug did against the study's primary goals, clouding its promise and spurring investor doubts.
Japanese drugmaker Chugai Pharmaceutical is planning a major expansion of its Singapore research outpost, laying out 476 million Singapore dollars ($374 million) over 7 years as it hits the gas on antibody research.
Japanese pharma giant Astellas is the latest drugmaker to make its clinical trial data available to outside researchers, increasing its R&D transparency but stopping short of some industry trailblazers.